Abbott posts Q2 earnings beat, lifts full-year outlook By Investing.com

Abbott Park, Illinois – Abbott Laboratories The American healthcare company (NYSE:) reported second-quarter earnings that beat Wall Street expectations and raised its full-year adjusted earnings guidance, signaling confidence in its diversified healthcare portfolio.

The company reported adjusted earnings per share of $1.14, beating analysts’ estimates of $1.11. Revenue for the quarter was $10.38 billion, closely in line with the consensus estimate of $10.37 billion.

The healthcare giant also raised its full-year 2024 earnings per share forecast to a range of $4.61 to $4.71, from its previous forecast, which now stands slightly above the midpoint of analysts’ consensus of $4.63. The updated guidance reflects strong underlying business performance, excluding specific items such as intangible amortization, restructuring and cost-cutting initiatives, which are expected to account for $1.31 per share.

“We delivered another quarter of strong growth in our core business,” said Robert Ford (NYSE:ABBOTT), chairman and chief executive officer. “We have a lot of positive momentum in the second half of the year and are raising our full-year outlook.”

The company’s second-quarter performance was boosted by 9.3% organic sales growth in its core businesses, led by a significant double-digit increase in the medical devices segment. This growth comes despite the continued phase-out of COVID-19 testing sales, which declined as the pandemic moved into a pandemic phase.

For the third quarter of 2024, Abbott expects adjusted diluted earnings per share to be in the range of $1.18 to $1.22, excluding specified items, which is also in line with analyst expectations.

Abbott’s strong fiscal quarter results and optimistic outlook reflect its success in navigating a challenging healthcare landscape, with strategic product launches and a focus on innovation. The company’s recent FDA approvals, including the Esprit™ BTK System and two new continuous glucose monitoring systems, Lingo™ and Libre Rio™, highlight its commitment to addressing unmet medical needs.

This article was created with the support of AI and reviewed by an editor. For more information, see our Terms and Conditions.

AbbottBeatearningsfullyearInvesting.comliftsOutlookposts
Comments (0)
Add Comment